PLUR - Pluri Inc Stock Price, Fair Value and News

6.10USD-0.17 (-2.71%)Delayed

Market Summary

USD6.10-0.17

Delayed

-2.71%

PLUR Stock Price

View Fullscreen

PLUR RSI Chart

PLUR Valuation

Market Cap

32.9M

Price/Earnings (Trailing)

-1.52

Price/Sales (Trailing)

43.48

Price/Free Cashflow

-1.93

PLUR Price/Sales (Trailing)

PLUR Profitability

Operating Margin

98.81%

Return on Equity

-1.2K%

Return on Assets

-59.41%

Free Cashflow Yield

-51.76%

PLUR Fundamentals

PLUR Revenue

Revenue (TTM)

756.0K

Rev. Growth (Yr)

-18.39%

Rev. Growth (Qtr)

-32.38%

PLUR Earnings

Earnings (TTM)

-21.6M

Earnings Growth (Yr)

30.57%

Earnings Growth (Qtr)

-7.91%

Breaking Down PLUR Revenue

Last 7 days

4.8%

Last 30 days

18.0%

Last 90 days

-8.1%

Trailing 12 Months

-8.1%

How does PLUR drawdown profile look like?

PLUR Financial Health

Current Ratio

6.05

PLUR Investor Care

Shares Dilution (1Y)

4.84%

Diluted EPS (TTM)

-4.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	756.0K	0	0	0
2023	1.4M	0	1.2M	963.4K
2022	0	1.2M	1.8M	1.6M
2021	0	0	0	0
2020	0	0	0	0
2019	53.0K	54.0K	106.0K	79.0K
2018	982.3K	50.0K	51.0K	52.0K
2017	0	0	0	1.9M
2016	2.2M	2.8M	0	0
2015	379.0K	379.0K	996.0K	1.6M
2014	480.0K	379.0K	379.0K	379.0K
2013	685.0K	779.0K	679.0K	579.0K
2012	0	716.0K	757.0K	721.0K
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pluri Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	aberman zami	acquired	-	-	44,100	-
Jan 23, 2024	yanay yaky	acquired	-	-	700,000	chief executive officer
Jan 23, 2024	franco-yehuda chen	acquired	-	-	355,000	chief financial officer
Jan 23, 2024	shemesh-rasmussen maital	acquired	-	-	38,150	-
Jan 23, 2024	levi rami avraham	acquired	-	-	37,100	-
Jan 23, 2024	birger pinhas doron	acquired	-	-	39,900	-
Jan 23, 2024	abony lorne kenneth	acquired	-	-	36,750	-
Dec 22, 2022	yanay yaky	acquired	-	-	334,821	chief executive officer
Dec 20, 2022	aberman zami	sold	-1,940	0.97	-2,000	-

Which funds bought or sold PLUR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-3.12	6,629	25,707	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-86.28	-26,953	6,334	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	sold off	-100	-30,461	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	9,424	9,424	-%
May 15, 2024	Altshuler Shaham Ltd	sold off	-100	-1,460	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	12,512	12,512	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-63.17	-307	322	-%
May 15, 2024	MORGAN STANLEY	reduced	-12.37	768	4,281	-%
May 14, 2024	Qube Research & Technologies Ltd	sold off	-100	-29.00	-	-%

Are Funds Buying or Selling PLUR?

Are funds buying PLUR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLUR

No. of Funds

Unveiling Pluri Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	shayna lp	8.1%	3,354,058	SC 13G/A
Feb 01, 2024	slager david mark	4.87%	2,041,939	SC 13G/A

Recent SEC filings of Pluri Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	S-8	Employee Benefits Plan
May 09, 2024	S-8	Employee Benefits Plan
May 09, 2024	10-Q	Quarterly Report
May 01, 2024	DEF 14A	DEF 14A
May 01, 2024	ARS	ARS
Apr 17, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Feb 14, 2024	SCHEDULE 13G	SCHEDULE 13G
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	8-K	Current Report

Peers (Alternatives to Pluri Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Pluri Inc News

Latest updates

Pluri Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-32.4%	71.00	105	493	87.00	468	848	9.00	780	156	263	455	646	301	208	116	23.00	56.00	-	-	50.00	25.00
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	-	-	-	2.00	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	-	22.00	-	-	-	48.00	4.00
S&GA Expenses	-100.0%	-	2,354	2,438	3,020	2,896	2,740	3,521	4,553	4,288	5,088	6,559	5,097	2,799	2,677	1,682	1,750	1,813	2,351	2,473	2,123	2,210
R&D Expenses	4.4%	3,094	2,964	3,366	4,333	3,785	4,503	5,400	6,273	6,541	6,391	7,824	7,999	6,203	5,956	5,742	5,572	5,826	6,264	8,421	7,432	7,765
Interest Expenses	0.9%	218	216	214	217	212	194	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	3.00	2.00	3.00	2.00	3.00	3.00	2.00	3.00	2.00
Net Income	-7.9%	-5,293	-4,905	-4,961	-7,624	-8,117	-6,121	-9,005	-9,865	-10,940	-11,432	-14,254	-12,554	-8,489	-8,136	-7,507	-6,370	-7,139	-7,760	-10,078	-8,683	-8,786
Net Income Margin	-15.0%	-28.60*	-24.86*	-23.20*	-22.40*	-20.88*	-20.04*	-34.14*	-592.47*	-648.03*	-668.46*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-13.8%	-4,291	-3,770	-5,960	-6,095	-6,348	-7,682	-8,626	-9,459	-9,892	-8,804	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.4%	36,390	41,564	44,542	50,797	56,241	59,927	59,754	68,065	79,127	81,184	83,747	93,538	79,174	52,263	58,950	65,532	23,020	24,860	27,573	31,310	18,731
Current Assets	-15.1%	27,367	32,252	35,258	41,409	46,687	50,140	49,723	57,747	64,313	60,153	62,826	67,371	49,820	45,250	42,691	48,461	17,819	19,227	21,471	26,371	13,196
Cash Equivalents	46.1%	7,991	5,468	5,253	5,360	3,677	8,818	10,031	11,413	24,930	19,222	15,218	31,838	12,851	8,300	7,587	9,229	7,835	8,271	4,674	5,186	10,238
Net PPE	-2.4%	769	788	768	688	681	673	707	739	787	890	1,176	1,499	1,809	2,089	2,260	2,516	2,777	3,067	3,372	3,838	4,265
Current Liabilities	-0.1%	4,526	4,530	4,322	5,621	5,377	5,284	5,018	6,829	7,822	9,595	10,365	11,517	9,916	9,996	8,345	7,987	7,200	6,991	7,843	8,158	8,247
Shareholder's Equity	-58.1%	1,845	4,399	11,038	13,355	19,064	24,966	26,901	32,186	40,143	39,840	48,907	57,151	68,136	41,148	48,948	56,101	14,169	15,910	17,527	21,821	8,627
Retained Earnings	-1.3%	-414,743	-409,450	-404,545	-399,584	-393,125	-385,501	-377,384	-371,263	-362,258	-352,393	-341,453	-330,021	-315,453	-301,199	-288,645	-280,156	-272,020	-264,513	-258,143	-251,004	-243,244
Additional Paid-In Capital	0.1%	414,387	413,849	413,446	412,939	412,189	408,692	401,576	401,302	400,351	392,233	390,360	387,172	383,589	342,347	337,593	336,257	286,189	280,423	275,670	272,825	251,870
Shares Outstanding	0.4%	5,229	5,210	5,181	5,156	5,134	4,149	4,070	4,063	4,016	4,017	4,000	3,995	-	-	-	-	-	-	-	-	-
Minority Interest	-0.8%	2,201	2,218	2,137	1,945	1,817	1,775	2,709	2,147	2,050	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	34,413	-	-	-	44,889	-	-	-	174,929	-	-	-	62,304	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.2%	-4,202	-3,649	-5,857	-2,897	-6,071	-6,280	-7,609	-8,427	-9,422	-9,863	-8,789	-9,597	-7,329	-7,843	-6,141	-6,322	-6,505	-6,301	-7,241	-6,673	-6,007
Share Based Compensation	7.9%	618	573	836	1,035	1,045	913	984	1,127	2,721	1,873	3,188	3,656	5,388	3,818	1,036	605	381	668	864	1,197	1,753
Cashflow From Investing	44.6%	5,668	3,919	5,802	4,324	-1,688	669	6,393	-2,955	7,663	14,315	-7,240	4,792	-23,828	7,572	4,199	-41,792	674	5,912	4,748	-18,515	6,775
Cashflow From Financing	-	-	-	-	-10.00	2,341	-	-	-	-	-	-	24,410	35,708	984	300	49,508	5,395	3,986	1,981	19,757	1,758

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PLUR Income Statement

2024-03-31

Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenues

$ 71

$ 87

$ 230

$ 176

Operating expenses:

Research and development expenses

(3,362)

(4,333)

(10,066)

(13,412)

Less: participation by the National Institute of Allergy and Infectious Diseases (“NIAID”), the Israeli Innovation Authority (“IIA”), Horizon Europe and other parties

268

166

1,015

1,189

Research and development expenses, net

(3,094)

(4,167)

(9,051)

(12,223)

General and administrative expenses

(2,511)

(3,020)

(7,303)

(8,655)

Operating loss

(5,534)

(7,100)

(16,124)

(20,702)

Interest expenses

(218)

(217)

(648)

(623)

Other financial income (expenses), net

362

(441)

1,290

(956)

Total financial income (expenses), net

144

(658)

642

(1,579)

Net loss

(5,390)

(7,758)

(15,482)

(22,281)

Net loss attributed to non-controlling interest

(97)

(134)

(323)

(419)

Net loss attributed to shareholders

$ (5,293)

$ (7,624)

$ (15,159)

$ (21,862)

Loss per share:

Basic net loss per share (in Dollars per share)

$ (1.01)

$ (1.52)

$ (2.92)

$ (5.04)

Weighted average number of shares used in computing basic net loss per share (in Shares)

^[1]

5,221,162

4,993,451

5,193,808

4,402,130

[1]	See note 1d regarding reverse stock split

PLUR Balance Sheet

2024-03-31

Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Jun. 30, 2023

CURRENT ASSETS:

Cash and cash equivalents

$ 7,081

$ 5,360

Short-term bank deposits

18,926

34,811

Restricted cash

273

269

Prepaid expenses and other current assets

1,087

969

Total current assets

27,367

41,409

LONG-TERM ASSETS:

Restricted bank deposits

637

627

Severance pay fund

459

439

Property and equipment, net

769

688

Operating lease right-of-use asset

7,151

7,633

Long-term deposit and other long-term assets

Total long-term assets

9,023

9,388

Total assets

36,390

50,797

CURRENT LIABILITIES

Trade payables

1,030

1,812

Accrued expenses

958

1,209

Operating lease liability

675

627

Accrued vacation and recuperation

810

873

Advances from customers

101

Other accounts payable

952

1,093

Total current liabilities

4,526

5,621

LONG-TERM LIABILITIES

Accrued severance pay

611

598

Operating lease liability

5,343

5,748

Loan from the European Investment Bank (“EIB”)

24,065

23,530

Total long-term liabilities

30,019

29,876

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY (DEFICIT)

Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of March 31, 2024, and June 30, 2023; Issued and outstanding: 5,228,737 and 5,155,687 shares as of March 31, 2024, and June 30, 2023, respectively

^[1],[2]

Additional paid-in capital

^[2]

414,387

412,939

Accumulated deficit

^[2]

(414,743)

(399,584)

Total shareholders’ (deficit) equity

^[2]

(356)

13,355

Non-controlling interests

^[2]

2,201

1,945

Total equity

^[2]

1,845

15,300

Total liabilities and equity

^[2]

$ 36,390

$ 50,797

[1]	Less than $1
[2]	See note 1d regarding reverse stock split

About Pluri Inc

Pluri Inc., a bio-technology company, creates cell-based products for commercial use. The company's technology platform, a 3D cell expansion system, advances novel cell-based solutions for a range of initiatives from medicine and climate change to food scarcity, animal cruelty, and other. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

CEO	Mr. Yaacov Yanay
WEBSITE	pluri-biotech.com
INDUSTRY	Biotechnology
EMPLOYEES	154

Pluri Inc Frequently Asked Questions

What is the ticker symbol for Pluri Inc? What does PLUR stand for in stocks?

PLUR is the stock ticker symbol of Pluri Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pluri Inc (PLUR)?

As of Fri May 17 2024, market cap of Pluri Inc is 32.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLUR stock?

You can check PLUR's fair value in chart for subscribers.

What is the fair value of PLUR stock?

You can check PLUR's fair value in chart for subscribers. The fair value of Pluri Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pluri Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLUR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pluri Inc a good stock to buy?

The fair value guage provides a quick view whether PLUR is over valued or under valued. Whether Pluri Inc is cheap or expensive depends on the assumptions which impact Pluri Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLUR.

What is Pluri Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PLUR's PE ratio (Price to Earnings) is -1.52 and Price to Sales (PS) ratio is 43.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLUR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pluri Inc's stock?

In the past 10 years, Pluri Inc has provided -0.318 (multiply by 100 for percentage) rate of return.